NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Zenas BioPharma, Inc. ZBIO
3 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$10.0M
▲ 100.0% vs FY2024
EPS · FY25
$-8.44
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-136.2%
Net margin · FY25
-3777.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 10.0M
Revenue, FY2025 · full 3-year series below
Revenue
Net income
The company lost 3777 cents on every revenue dollar this year.
Per share
USD -8.44
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-136.2%
Return on equity, FY2025
ROE
Operating margin-3830.6%
Net margin-3777.4%
Return on assets-100.2%
Each USD of equity lost 136 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 383.6M
total assets, end of FY2025
Total assetsUSD 383.6M
EquityUSD 242.1M
CashUSD 110.6M
Gross debtUSD 78.6M
Net debtUSD -32.0M
Current ratio5.61×
The company holds more cash than debt.
History
3 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
Revenue $B
0.0
0.0
0.1
Operating income $B
−0.4
−0.2
−0.0
EBITDA $B
−0.4
−0.2
−0.0
Income tax $B
−0.0
0.0
0.0
Net income $B
−0.4
−0.2
−0.0
EPS, diluted $
−8.44
−11.89
−24.25
Dividend / sh $
·
·
·
Payout %
·
·
·
ROE %
−136.2
−362.0
·
Shares out B
0.05
0.04
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
9 of 9
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed